As marijuana reform continues to stagnate in the Wisconsin legislature, bipartisan and bicameral lawmakers have come together to introduce a new bill that would create a psilocybin research pilot program in the state.
Sens. Jesse James (R) and Dianne Hesselbein (D), as well as Reps. Nate Gustafson (R) and Clinton Anderson (D), are sponsoring the legislation, which would focus on exploring the therapeutic potential of the psychedelic in the treatment of post-traumatic stress disorder (PTSD) among veterans.
The pilot program would be facilitated through the University of Wisconsin at Madison, which already operates a multidisciplinary psychedelics research division that launched in 2021.
Veterans who are 21 and older with diagnosed treatment-resistant PTSD would be eligible to participate in the program. Psilocybin would need to be provided through existing pathways under the federal Food and Drug Administration (FDA), which has designated the psychedelic as a “breakthrough therapy.”